Study: Bypass surgery outperforms Boston Scientific's Taxus

A study of 3,000 patients in 85 U.S. and European hospitals found that 17.8% of those who received Boston Scientific's Taxus drug-coated stent died, experienced a stroke or heart attack, or underwent repeat procedures after a year, compared with 12.1% of those who got bypass surgery. An analysis of the company-sponsored study found no marked difference regarding safety between the two procedures within the first year -- a result that gives patients more options, a cardiologist said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC